Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.47 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.39 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.39 |
| ▸ | PREP | P48147 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24536622 | 0.95 | HPGD (0.48) | ESR2NR1H2HPGDUSP2SMN1; SMN2 | |
| SCHEMBL16925538 | 0.94 | HPGD (0.50) | ESR2NR1H2HPGDUSP2SMN1; SMN2 | |
| SCHEMBL1063509 | 0.90 | ESR2 (0.52) | ESR2NR1H2HPGDUSP2SMN1; SMN2 | |
| SCHEMBL689236 | 0.87 | HPGD (0.49) | ESR2NR1H2HPGDUSP2SMN1; SMN2 | |
| SCHEMBL21876055 | 0.86 | USP2 (0.50) | ESR2NR1H2HPGDUSP2SMN1; SMN2 | |
| SCHEMBL1488353 | 0.82 | USP2 (0.48) | ESR2NR1H2HPGDUSP2SMN1; SMN2 | |
| SCHEMBL13160 | 0.81 | ESR2 (0.48) | ESR2NR1H2HPGDUSP2SMN1; SMN2 | |
| SCHEMBL3748000 | 0.81 | ESR2 (0.48) | ESR2NR1H2HPGDUSP2SMN1; SMN2 | |
| SCHEMBL18084854 | 0.80 | USP2 (0.50) | ESR2NR1H2HPGDUSP2SMN1; SMN2 | |
| SCHEMBL16078939 | 0.80 | ESR2 (0.47) | ESR2NR1H2HPGDUSP2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 152 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116143695-B | Synthesis method of 1, 1-difluoro-5-azaspiro [2.5] octane hydrochloride | 上海麦克林生化科技股份有限公司 | 2024-04-05 | — | — | CN | claimed |
| CN-116143695-A | Synthesis method of 1, 1-difluoro-5-azaspiro [2.5] octane hydrochloride | 上海麦克林生化科技股份有限公司 | 2023-05-23 | — | — | CN | claimed |
| US-12569564-B2 | Spirocyclic MDM2 modulator and uses thereof | NEWAVE PHARMACEUTICAL INC. (US) | 2026-03-10 | — | — | US | disclosed |
| US-20250304560-A1 | MODULATORS OF NLRP3 INFLAMMASOME AND RELATED PRODUCTS AND METHODS | Neumora Therapeutics, Inc. | 2025-10-02 | — | — | US | disclosed |
| US-20250276964-A1 | Benzisoxazole Derivatives and Uses thereof | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2025-09-04 | — | — | US | disclosed |
| EP-4522600-A1 | MODULATORS OF NLRP3 INFLAMMASOME AND RELATED PRODUCTS AND METHODS | Neumora Therapeutics, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| US-20250073340-A1 | SPIROCYCLIC MDM2 MODULATOR AND USES THEREOF | NEWAVE PHARMACEUTICAL INC. | 2025-03-06 | — | — | US | disclosed |
| EP-4493556-A1 | NLRP3 MODULATORS | Zomagen Biosciences Ltd (US) | 2025-01-22 | — | — | EP | disclosed |
| CN-119301116-A | NLRP3 modulators | 祖玛珍生物科学有限公司 | 2025-01-10 | — | — | CN | disclosed |
| US-12071425-B2 | Phenoxy-pyridyl-pyrimidine compounds and methods of use | GENENTECH, INC. (US) | 2024-08-27 | — | — | US | disclosed |
| US-20240262806-A1 | INHIBITORS OF NLRP3 | PCT THERAPEUTICS, INC. (US) | 2024-08-08 | — | — | US | disclosed |
| EP-1694663-A1 | NOVEL BENZOFURAN DERIVATIVES, WHICH CAN BE USED IN PROPHYLAXIS OR TREATMENT OF 5-HT6 RECEPTOR-RELATED DISORDER | Biovitrum Aktiebolag (SE) | 2006-08-30 | — | — | EP | disclosed |
| WO-2006085212-A2 | CONDENSED ISOXALINE DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASE TYPE-IV | RANBAXY LABORATORIES LIMITED (IN) | 2006-08-17 | — | — | WO | disclosed |
| WO-2005058858-A1 | NOVEL BENZOFURAN DERIVATIVES, WHICH CAN BE USED IN PROPHYLAXIS OR TREATMENT OF 5-HT6 RECEPTOR-RELATED DISORDER | BIOVITRUM AB (SE) | 2005-06-30 | — | — | WO | disclosed |
| US-20040186097-A1 | Heterocyclic piperidines as modulators of chemokine receptor activity | KO SOO S (US) | 2004-09-23 | — | — | US | disclosed |
| US-6759411-B2 | ANTIHISTAMINES, ANTIALLERGENS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-07-06 | — | — | US | disclosed |
| US-20020119980-A1 | Heterocyclic piperidines as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-08-29 | — | — | US | disclosed |
| US-6331545-B1 | TREATING ASTHMA, ALLERGIC RHINITIS, ATOPIC DERMATITIS, AND INFLAMMATORY BOWEL DISEASES | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2001-12-18 | — | — | US | disclosed |
| EP-1140834-A1 | HETEROCYCLIC PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Du Pont Pharmaceuticals Company (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000035877-A1 | HETEROCYCLIC PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186097-A1 | Heterocyclic piperidines as modulators of chemokine receptor activity | CCR3, CCR1, CCR4 | ESR2 2779/4885NR1H2 397/4885HPGD 446/4885 |
| US-20250304560-A1 | MODULATORS OF NLRP3 INFLAMMASOME AND RELATED PRODUCTS AND METHODS | NLRP3, NLRP1, PYCARD | ESR2 1310/4885NR1H2 155/4885HPGD 2430/4885 |
| US-20020119980-A1 | Heterocyclic piperidines as modulators of chemokine receptor activity | CCR3, CCR1, CCR4 | ESR2 2779/4885NR1H2 397/4885HPGD 446/4885 |
| US-20240262806-A1 | INHIBITORS OF NLRP3 | NLRP3, NOD1, NLRP1 | ESR2 1861/4885NR1H2 143/4885HPGD 1920/4885 |
| US-20250276964-A1 | Benzisoxazole Derivatives and Uses thereof | HBZ, ZFX, WIZ | ESR2 3184/4885NR1H2 1557/4885HPGD 1767/4885 |
| US-12071425-B2 | Phenoxy-pyridyl-pyrimidine compounds and methods of use | XBP1, ERN1, ESR2 | ESR2 3/4885NR1H2 146/4885HPGD 1032/4885 |
| US-20250073340-A1 | SPIROCYCLIC MDM2 MODULATOR AND USES THEREOF | FOXM1, MDM2, FOXO1 | ESR2 321/4885NR1H2 449/4885HPGD 1572/4885 |
| US-12569564-B2 | Spirocyclic MDM2 modulator and uses thereof | MDM2, TP53, XIAP | ESR2 534/4885NR1H2 333/4885HPGD 2935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.